GENERIC NAME: dasatinib
BRAND NAME: Sprycel
DRUG CLASS AND MECHANISM: Dasatinib is an oral medication used for treating chronic myeloid leukemia and acute lymphoblastic leukemia. It is classified as a kinase inhibitor. Kinase inhibitors include Erlotinib (Tarceva), gefitinib (Iressa), imatinib (Gleevec), nilotinib (Tasigna), pazopanib (Votrient), sunitinib (Sutent), and vandetanib (Caprelsa). Kinase inhibitors prevent the growth of tumors by reducing the action of proteins that control cell division, growth, and survival. These proteins are usually present in larger quantities or are more active in cancer cells. By reducing the activity of these proteins, growth and survival of cancer cells are reduced. The FDA approved dasatinib in June 2006.
SIDE EFFECTS: Common side effects are:
- fluid retention,
- nausea and vomiting,
- abdominal distention,
- weight loss or gain,
- dizziness, and
- muscle pain.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.